Compare Dow Inc (DOW) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dow Inc vs Illumina, Inc. — how do they compare? Dow Inc trades at $30.77 (market cap $22.58B), while Illumina, Inc. trades at $190.14 (market cap $29.12B). The key difference: Illumina, Inc. is the larger of the two by market cap, and Dow Inc pays a 4.48% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| DOW | ILMN | |
|---|---|---|
Market Cap | $22.58B | $29.12B |
Sector | Basic Materials | Health |
52-Week High | $41.87 | $205.10 |
52-Week Low | $20.65 | $91.00 |
Enterprise Value | $38.27B | $30.48B |
Dividend Yield | 4.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOW trades at $30.58, up 4.23% today, with a neutral technical signal and bullish moving averages. Recent earnings have consistently beaten estimates, but the company reported a net loss of -$2.62B in 2025, with declining revenue and negative profit margins. Cash flow from operations improved in 2025 to $1.03B, though debt levels have risen. The stock is trading below the analyst consensus price target of $35.11, with a mixed analyst rating of 33% buy, 53% hold, and 14% sell.
The outlook is cautious; while earnings beats and a dividend payment provide some support, persistent net losses, revenue declines, and rising debt pose significant risks. Investors should weigh the potential for operational turnaround against fundamental weaknesses and macroeconomic pressures on the chemicals sector.
Illumina (ILMN) trades at $191.79, up 2.04% today, with a neutral technical signal and strong fundamental recovery. The stock shows bullish moving averages but faces resistance near $194. Recent earnings beats and a return to profitability in 2025, with $850M net income, highlight operational turnaround. Revenue remains stable around $4.3B, supported by robust gross margins of 66.38%.
Outlook is positive with analyst consensus Buy rating and $201.58 price target, though high P/E of 35.98 poses valuation risk. Key opportunities include sequencing demand and AI partnerships, while risks involve debt levels and competitive pressures. Institutional activity is mixed, with some funds increasing stakes amid earnings momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dow Inc
Dow Inc is a diversified chemical manufacturing company. It combining science and technology to develop innovative solutions that are essential to human progress. Dow's portfolio is comprised of six global business units, organized into three operating segments: Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings.
Read more on DOW →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
